Tatva Chintan Pharma Chem announced Q2FY23 results: Consolidated: YoY Q2FY23 vs Q2FY22: Revenue from Operations for the quarter was Rs. 901 million, which declined by 27% EBITDA for the quarter was Rs. 112 million, which declined by 68% EBIDTA Margin for the quarter was at 12% Net Profit for the quarter was Rs. 71 million, which declined by 78% Net Profit Margin for the quarter was at 8% Basic and Diluted EPS for the quarter was Rs. 3.21 per share YoY H1FY23 vs H1FY22: Revenue from Operations for the half year was Rs. 1,785 million, which declined by 23% EBITDA for the half year was Rs. 264 million, which declined by 57% EBIDTA Margin for the half year was at 15% Net Profit for the half year was Rs. 169 million, which declined by 70% Net Profit Margin for the half year was at 9% Basic and Diluted EPS for the half year was Rs. 7.63 per share Commenting on Q2FY23 Results, Mr. Chintan Shah, Managing Director, said, EBITDA during this quarter was Rs. 112 million, a decline of 68% YoY and 27% QoQ. EBIDTA includes a forex loss of Rs. 31.85 million, so the actual operational EBIDTA during the quarter is Rs. 143.62 million which translates into an EBIDTA margin of 16%. Forex loss is mainly because of the MTM of the forward contract due to the depreciating rupee. PAT was Rs. 71 million, a decline of 78% YoY and 27% QoQ. Compared to the QoQ basis, the profitability has dropped due to an increase in costs such as power & fuel, packing and employee costs during this quarter Result PDF
Conference Call with Tatva Chintan Pharma Chem Ltd. Management and Analysts on Q1FY23 Performance and Outlook. Listen to the full earnings transcript.
Tatva Chintan Pharma Chem Announced Q1FY23 results: Consolidated (YoY Q1FY23 compared with Q1FY22): Revenue from Operations for the quarter was Rs 884 million, declined by 17% EBITDA (excluding other income) for the quarter was Rs 152 million, declined by 42% EBIDTA Margin for the quarter was at 17% vs 25% in Q1FY22 Net Profit for the quarter was Rs 98 million declined by 58% Net Profit Margin for the quarter was at 11% vs 22% in Q1FY22 Basic and Diluted EPS for the quarter was Rs 4.42 per share vs Rs 11.5 in Q1FY22 Commenting on Q1FY23 Results, Mr. Chintan Shah, Managing Director, said, "on a full year basis FY22, the total revenue was Rs 4,336 million, out of which SDA contributed Rs 2,248 million. The other three product categories viz. PTC, ES and PASC together contributed Rs 2,058 million for the whole year, so on an average the quarterly sales of these three categories put together was at Rs 515 million against this during Q1FY23 we have achieved revenue of Rs 818 million in these three product categories showing a growth of nearly 60% which clearly reflects the growth potential of PTC, ES and PASC." Result PDF
Conference Call with Tatva Chintan Pharma Chem Management and Analysts on Q4FY22 Performance and Outlook. Listen to the full earnings transcript.
Tatva Chintan Pharma Chem's profit falls 17% YoY in Q4FY22, revenue down 9% Tatva Chintan Pharma Chem announced Q4FY22 results: FY22: Revenue from Operations for the year FY22 was Rs 4,336 million higher by 44% vs FY21 EBITDA was Rs 1,171 million higher by 64% EBIDTA Margin for the year was at 27% vs 24% in FY21 Net Profit was Rs 959 million higher by 83% Net Profit Margin for the year was at 22% vs 17% in FY21 Basic and Diluted EPS was Rs 44.59 per share vs Rs 26.02 in FY21 Q4FY22 (YoY): Revenue from Operations for the quarter was Rs 985 million, declined by 9% EBITDA for the quarter was Rs 223 million, declined by 18% EBIDTA Margin for the quarter was at 23% vs 25% in Q4FY21 Net Profit for the quarter was Rs 175 million declined by 17% Net Profit Margin for the quarter was at 18% vs 19% in Q4FY21 Basic and Diluted EPS for the quarter was Rs 7.9 per share vs Rs 10.5 in Q4FY21 Commenting on the year FY22 Mr. Chintan Shah, Managing Director, said, "FY22 has been a special year, as for the first time, we crossed the revenue mark of Rs 4,000 million, we crossed an PBT of more than Rs 1,000 million, our exports revenue crossed the mark of Rs 3,000 million for the first time and in fact our export revenue of FY22 has exceeded the total revenue of FY21. Last and most memorable was successfully getting listed on Indian Stock Exchange. We are pleased to inform you that on 'together for sustainability' platform, we have drastically improved our Audit score from 54% to 87%. This is a matter of pride for TATVA CHINTAN and it also demonstrates our genuine efforts in moving towards sustainable solutions. Our approach of being an integrated manufacturer, producing niche specialty chemical, having leadership position across product categories, diversified geographically with 79% exports as on FY22, focus on green chemistry by using cutting edge technology, in-house R&D; facility with 24 employees including 10 senior highly qualified scientists has helped us steadily grow our presence and more importantly helped grow the customer’s confidence in TATVA CHINTAN, despite the turbulent macroeconomic situation of covid lockdowns and geopolitical tensions globally. We got listed on NSE/BSE on 29 July 2021, out of our net IPO proceeds of Rs 2,072.81 million, Rs 129.59 million have been utilized during Q4FY22 taking the total amount utilized to Rs 640.97 million as on 31 March 2022. The expansion is underway at our Dahej SEZ manufacturing plant and at our R&D; facility at Vadodara." Result PDF
Conference Call with Tatva Chintan Pharma Chem Management and Analysts on Q3FY22 Performance and Outlook. Listen to the full earnings transcript.
Chemicals and petrochemicals company Tatva Chintan Pharma Chem Ltd. declares Q3FY22 result: Consolidated Results at Glance (YoY - Q3FY22 compared with Q3FY21) Revenue from Operations for the quarter was Rs 1,046.70 million higher by 31% EBITDA for the quarter was Rs 285.32 million higher by 13% EBIDTA Margin for the quarter was at 27.26% Net Profit for the quarter was Rs 228.07 million higher by 9% Net Profit Margin for the quarter was at 21.79% Basic and Diluted EPS for the quarter was Rs 10.29 per share Consolidated Results at Glance (YoY - 9MFY22 compared with 9MFY21) Revenue from Operations for the nine months was Rs 3,351.17 million higher by 75% EBITDA for the nine months was Rs 948.27 million higher by 113% EBIDTA Margin for the nine months was at 28.30% Net Profit for the nine months was Rs 783.64 million higher by 152% Net Profit Margin for the nine months was at 23.38% Basic and Diluted EPS for the nine months was Rs 36.82 per share Commenting on the Q3 & 9M performance Mr. Chintan Shah, Managing Director, said, during the quarter I am pleased to inform you that we are very well on our way of being recognized as a niche player in the speciality chemical space with our focus on manufacturing Phase Transfer Catalyst, Structure Directing Agents, Electrolyte Salts, Pharma & Agrochemical Intermediates and Speciality Chemicals with PTC comprising 24%, SDAs comprising 51%, Electrolyte Salts comprising 2% and PASC comprising 22% of the revenue taking the revenue till date i.e. 9MFY22 at Rs 3,351.17 million as compared to 3,003.59 million during FY21. The company posted an EBIDTA margin of 28.30% during 9MFY22 as compared to 23.85% during FY21. During the quarter, exports comprised 80% of the revenue. We have a clear focus on adopting green chemistry processes supported by our state-of-the-art research and development facility and manufacturing plants. With the wide range of applications of our products, TCPCL can cater to customers across wide spectrum of chemical Industries which ensures a sustainable business model. Diversified product portfolio has helped accelerate our growth. We got listed on NSE/BSE on 29 July 2021, out of our net IPO proceeds of Rs 2,072.81 million, Rs 114.53 million have been utilized during Q3FY22 taking the total amount utilized to Rs 511.38 million as on 31 December 2021. The capacity expansion is underway at our Dahej SEZ manufacturing plant and at our R&D; facility at Vadodara. During the quarter, we appointed Mr Ashok Bothra as Chief Financial Officer (CFO) and Key Managerial Personnel (KMP) of the company with effect from 3’ December 2021. Result PDF